“Patients with chronic … B or C may have a threefold risk … liver dysfunction after receiving antituberculosis treatment.[1,2] A proinflammatory environment induced by actively replicating the hepatitis virus may alter the detoxication … and increase drug toxicity.[3] At this time, the safety of other drugs should be reevaluated.”